Avenue Therapeutics Appoints New CMO, CDO, and Directors
Ticker: ATXI · Form: 8-K · Filed: Sep 27, 2024 · CIK: 1644963
Sentiment: neutral
Topics: management-change, board-election
TL;DR
Avenue Therapeutics beefs up leadership with new CMO, CDO, and board members.
AI Summary
Avenue Therapeutics, Inc. announced on September 23, 2024, the appointment of Dr. James R. Scopa as Chief Medical Officer and Dr. Robert L. Smith as Chief Development Officer. The company also reported the election of two new directors, Ms. Jennifer L. Jones and Mr. David M. Lee, to its Board of Directors.
Why It Matters
The appointment of key executives and new board members can signal a strategic shift or renewed focus for the company, potentially impacting its future development and market position.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- Dr. James R. Scopa (person) — Appointed Chief Medical Officer
- Dr. Robert L. Smith (person) — Appointed Chief Development Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- Mr. David M. Lee (person) — Elected to Board of Directors
- September 23, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. James R. Scopa has been appointed as the Chief Medical Officer.
Who is the new Chief Development Officer?
Dr. Robert L. Smith has been appointed as the Chief Development Officer.
When was the earliest event reported in this filing?
The earliest event reported was on September 23, 2024.
How many new directors were elected to the Board?
Two new directors, Ms. Jennifer L. Jones and Mr. David M. Lee, were elected to the Board.
What is Avenue Therapeutics, Inc.'s principal executive office address?
The principal executive office is located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.
Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-09-27 16:18:06
Filing Documents
- atxi20240927_8k.htm (8-K) — 26KB
- ex_727900.htm (EX-10.1) — 29KB
- 0001437749-24-030185.txt ( ) — 193KB
- atxi-20240923.xsd (EX-101.SCH) — 3KB
- atxi-20240923_def.xml (EX-101.DEF) — 11KB
- atxi-20240923_lab.xml (EX-101.LAB) — 15KB
- atxi-20240923_pre.xml (EX-101.PRE) — 11KB
- atxi20240927_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2024, (the " Grant Date "), the Compensation Committee (the " Compensation Committee ") of the Board of Directors (the " Board ") of Avenue Therapeutics, Inc. (the " Company ") and the Board, respectively, approved the granting of equity awards under the Company's 2015 Incentive Plan, as amended (the " Plan "), to certain named executive officers as follows: (a) an award of 170,000 restricted stock units to Alexandra MacLean, M.D. (" MacLean "), the Company's Chief Executive Officer (the " MacLean RSUs "), and (b) an award of 65,000 restricted stock units to David Jin (" Jin "), the Company's Interim Principal Financial Officer and Chief Operating Officer (the " Jin RSUs " and together with the MacLean RSUs, the " RSUs "). The RSUs vest in four equal installments on each of the following dates: September 30, 2024, December 31, 2024, September 20, 2025, and September 20, 2026 (each an " RSU Vesting Date "), provided that the grantee provides continuous service to the Company from the Grant Date through the applicable RSU Vesting Date and subject to the other terms of the restricted stock unit agreement (" RSU Agreement "). Once vested, the settlement of the RSUs will be deferred until the earlier of the tenth business day of January of the year following termination of service of the recipient to the Company under certain conditions and/or the occurrence of a Change in Control event (as defined in the Plan). The RSUs were granted pursuant to an RSU Agreement, the form of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 5.02.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit Number Description 10.1 Form of Restricted Stock Unit Agreement. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: September 27, 2024 By: /s/ David Jin David Jin Interim Principal Financial Officer and Chief Operating Officer